GA
SPTX

General Atlantic’s Seaport Therapeutics SPTX Stock Holding History

General Atlantic’s Portfolio SPTX Stock Details SPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133M Buy
+6,101,582
New +$107M 4.56% 7

Other funds holding SPTX

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TGV
TRV GP VI Boston, Massachusetts $232M AUM 247.08% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

General Atlantic's SPTX Position: Q2 2026 in Review

General Atlantic opened a new position in Seaport Therapeutics (SPTX) in Q2 2026: 6,101,582 shares worth $133M. The stake represents 4.56% of the portfolio and ranks #7 among its holdings.

47 funds tracked by Wall St. Rank hold SPTX as of Q2 2026.

  • General Atlantic held 6,101,582 shares of Seaport Therapeutics worth $133M as of Q2 2026.
  • Seaport Therapeutics was a new General Atlantic position in Q2 2026.
  • Seaport Therapeutics made up 4.56% of General Atlantic's portfolio in Q2 2026, its #7 holding.
  • 47 funds tracked by Wall St. Rank held Seaport Therapeutics as of Q2 2026.

Based on General Atlantic's 13F filing for Q2 2026, filed 14 Aug 2026.